Beam Therapeutics CEO John Evans sells $1.19m in company stock

Beam Therapeutics CEO John Evans sold approximately $1.19 million worth of the company's stock on October 15 and 16, 2026. This was done through a pre-arranged Rule 10b5-1 trading plan. On the 15th, he exercised options to acquire an additional 25,000 shares at $1.03 each, then sold those shares the next day at prices between $23.23 and $23.84, resulting in a weighted average sale price of $23.566.

The following day, Evans repeated the process, exercising options for 25,000 more shares at $1.03 and selling them at prices ranging from $23.66 to $24.56, with a weighted average sale price of $23.9838. The total shares traded over the two days amounted to 50,000, valued at $1,188,745. Following these transactions, Evans directly owns 1,047,205 shares of Beam Therapeutics common stock, with 103,000 shares held indirectly by his trust.

The current stock price is $23.47, down 15% year-to-date, and the company's beta of 2.2 indicates high volatility typical of biotech stocks. Analysts note that Beam Therapeutics appears overvalued at its current price.